← Back to search results

ClosedFind a Tender · UK4

PACE Interim Impact Report

Buyer: MEDICINES DISCOVERY CATAPULT LIMITED →

Participate on procontract.due-north.com ↗External submission platform

BuyerMEDICINES DISCOVERY CATAPULT LIMITED
StatusClosed
Deadline9 Jan 2026
Value£50,000
Published9 Dec 2025

What is being bought

PACE (Pathways to Antimicrobial Clinical Efficacy) is a £30 million initiative supporting and funding early-stage innovation in medicines and diagnostics, aimed at tackling AMR. It was established in September 2023 and is a collaboration between Innovate UK (IUK), LifeArc, and Medicines Discovery Catapult (MDC) - three leaders in the UK's health innovation and research community. PACE brings together the funding, resources, and partnerships to help innovators progress their early-stage antimicrobial drug and diagnostics projects with greater speed, support and confidence - giving the best AMR innovations the greatest chance of success. PACE will create a path to value through 3 strategic goals which will be underpinned by effective programme management and delivery: Grow a pipeline of high-quality antimicrobial drugs and associated diagnostics aligned with unmet needs and route to patient impact. Provide innovative researchers in Academia and SMEs located globally the funding, advice and support they need to build de-risked and investment ready assets Convene collaboration network(s) to identify barriers to innovation, advance programmes and drive new collaborative R&D. It is a requirement of MDC's grant funding agreement with Innovate UK and LifeArc that the outcomes and long-term impacts of PACE activities are assessed at key time points throughout the programme's timeline. The PACE programme is funded for an initial term of five years and as of April 2026 will reach its midway point in this funding cycle and so there is a need to conduct an interim review of progress towards expected outcomes. Findings from this interim review will directly inform programme refinement. Key to this will be the opportunity to gather feedback and learning from Round 1 beneficiaries and partners on the PACE Academy, the project management process, and the use of Enabling projects so far. It will also allow the programme to capture the experiences of beneficiaries from Round 2 to date. This will provide learning in how best to support the Round 2 beneficiaries and for the future Round 3 of funding which will be targeted at a second group of therapeutic companies. It is expected that findings from the interim review will directly inform the need and shape for PACE beyond the first 5 - year funded term. The PACE programme is now looking for an external provider to develop and produce an interim impact review and report (that will build upon the existing baseline impact study completed in June 2025) to understand how key activities are progressing towards expected outcomes which can be compared to the findings from the baseline study and at the endline stage. The overall purpose of the impact evaluation and this interim review is to be able to assess the impact of PACE on the AMR drug development ecosystem and on the development of drugs and diagnostics.

Delivery location

UK, GB

Categories

Business and management consultancy services 79410000

Lot details

Lot 1

No lot description published.

Statusactive
Value£50,000
Contract periodFrom 2 Feb 2026 to 31 Jul 2026
SME suitabilitySuitable for SMEs

Award criteria
Quality (80%)
Price (20%)

What is included

ItemCategoryQuantity
1Business and management consultancy servicesNot published

Comparable-procurement analytics

Benchmarked against retained Find a Tender procedures with CPV division 79. The category anchor is Business and management consultancy services (79410000); this is a deliberately broad market comparator. The comparison is shown at several levels rather than pretending one company or region is always the best benchmark.

Comparison setProceduresReported bids per procedureNamed award suppliersPrice evidence
Market: CPV division 799,7714 median · 32.6 average (3,929 of 9,771 with a bid count)3.2 average (4,395 of 9,771 with named award suppliers)1 comparable price pairs
Same buyer1Not published1 average (1 of 1 with named award suppliers)Not published
Delivery region: UK2,7014 median · 64.3 average (1,037 of 2,701 with a bid count)5.1 average (1,220 of 2,701 with named award suppliers)Not published
Similar published value (0.5×–2×)5287 median · 8.3 average (3 of 528 with a bid count)1 average (3 of 528 with named award suppliers)Not published

“Reported bids” is an official aggregate, sometimes reported per lot; it is the closest available competition measure. “Named award suppliers” are winners, not all applicants.

Price-outcome signal

Not enough comparable procedures currently publish both a GBP tender value and a usable lowest-valid-bid value to calculate a responsible price-reduction benchmark. Tenderline deliberately does not infer a saving from named award suppliers or from missing award values.

Procurement strategy & market signals

Framework agreementNot published
Dynamic purchasing systemNot published
Competitive procurementNot published
Recurring requirementNot published
Procurement method rationaleNot published
Rationale classificationsNot published
Special regimeNot published
Covered byNot published
Submission policyallowed
Selection criteriaNot published
Risk detailsNot published

Planning & early market engagement

BudgetNot published
No-engagement rationaleNot published
Planning documents0
Planning milestones0

No planning milestones published.

Related procurements

No linked framework, prior procurement or reprocurement published.

Documents & submission route

Source data inventory

Diagnostic view. “Not published” means this current release does not provide a value.

OCIDocds-h6vhtk-05f160
Latest release ID080894-2025
Latest release timestampTue Dec 09 2025 09:26:03 GMT+0000 (Coordinated Universal Time)
Sourcefind-a-tender
Official notice URLhttps://www.find-tender.service.gov.uk/Notice/080894-2025
Tender statusactive
Procurement methodopen
Procurement method detailsBelow threshold - open competition
Main procurement categoryservices
Above thresholdNo
Legal basis2023/54
Tender period: startNot published
Tender period: end2026-01-09T14:00:00Z
Expression of interest deadlineNot published
Enquiry deadline2025-12-23T14:00:00Z
Award period: startNot published
Award period: endNot published
Submission method detailshttps://procontract.due-north.com/Advert/?advertId=37a0881b-dfd4-f011-813a-005056b64545
Submission languagesNot published
Electronic catalogue policyNot published
Total tender value£50,000
Tender lots in source1
Tender items in source1
Tender documents in source1
Awards in latest release0
Contracts in latest release0
Parties in latest release1

Notice history

DateEventReference
9 Dec 2025tenderUpdate080894-2025
9 Dec 2025tender080889-2025

All source data

Unmodified official OCDS data retained by Tenderline for this procurement process.

Complete current OCDS release JSON
{
  "id": "080894-2025",
  "tag": [
    "tenderUpdate"
  ],
  "date": "2025-12-09T09:26:03Z",
  "ocid": "ocds-h6vhtk-05f160",
  "buyer": {
    "id": "GB-COH-09928547",
    "name": "MEDICINES DISCOVERY CATAPULT LIMITED"
  },
  "tender": {
    "id": "ocds-h6vhtk-05f160",
    "lots": [
      {
        "id": "1",
        "value": {
          "amount": 50000,
          "currency": "GBP",
          "amountGross": 60000
        },
        "status": "active",
        "suitability": {
          "sme": true
        },
        "awardCriteria": {
          "criteria": [
            {
              "name": "Quality",
              "type": "quality",
              "numbers": [
                {
                  "number": 80,
                  "weight": "percentageExact"
                }
              ]
            },
            {
              "name": "Price",
              "type": "price",
              "numbers": [
                {
                  "number": 20,
                  "weight": "percentageExact"
                }
              ]
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2026-07-31T23:59:59+01:00",
          "startDate": "2026-02-02T00:00:00Z"
        }
      }
    ],
    "items": [
      {
        "id": "1",
        "relatedLot": "1",
        "deliveryAddresses": [
          {
            "region": "UK",
            "country": "GB",
            "countryName": "United Kingdom"
          }
        ],
        "additionalClassifications": [
          {
            "id": "79410000",
            "scheme": "CPV",
            "description": "Business and management consultancy services"
          }
        ]
      }
    ],
    "title": "PACE Interim Impact Report",
    "value": {
      "amount": 50000,
      "currency": "GBP",
      "amountGross": 60000
    },
    "status": "active",
    "documents": [
      {
        "id": "080894-2025",
        "url": "https://www.find-tender.service.gov.uk/Notice/080894-2025",
        "format": "text/html",
        "noticeType": "UK4",
        "description": "Tender notice on Find a Tender",
        "documentType": "tenderNotice",
        "datePublished": "2025-12-09T09:26:03Z"
      }
    ],
    "legalBasis": {
      "id": "2023/54",
      "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents",
      "scheme": "UKPGA"
    },
    "description": "PACE (Pathways to Antimicrobial Clinical Efficacy) is a £30 million initiative supporting and funding early-stage innovation in medicines and diagnostics, aimed at tackling AMR. It was established in September 2023 and is a collaboration between Innovate UK (IUK), LifeArc, and Medicines Discovery Catapult (MDC) - three leaders in the UK's health innovation and research community.\nPACE brings together the funding, resources, and partnerships to help innovators progress their early-stage antimicrobial drug and diagnostics projects with greater speed, support and confidence - giving the best AMR innovations the greatest chance of success. PACE will create a path to value through 3 strategic goals which will be underpinned by effective programme management and delivery:\nGrow a pipeline of high-quality antimicrobial drugs and associated diagnostics aligned with unmet needs and route to patient impact.\nProvide innovative researchers in Academia and SMEs located globally the funding, advice and support they need to build de-risked and investment ready assets\nConvene collaboration network(s) to identify barriers to innovation, advance programmes and drive new collaborative R&D.\nIt is a requirement of MDC's grant funding agreement with Innovate UK and LifeArc that the outcomes and long-term impacts of PACE activities are assessed at key time points throughout the programme's timeline.  The PACE programme is funded for an initial term of five years and as of April 2026 will reach its midway point in this funding cycle and so there is a need to conduct an interim review of progress towards expected outcomes.\nFindings from this interim review will directly inform programme refinement. Key to this will be the opportunity to gather feedback and learning from Round 1 beneficiaries and partners on the PACE Academy, the project management process, and the use of Enabling projects so far.  It will also allow the programme to capture the experiences of beneficiaries from Round 2 to date.  This will provide learning in how best to support the Round 2 beneficiaries and for the future Round 3 of funding which will be targeted at a second group of therapeutic companies.  It is expected that findings from the interim review will directly inform the need and shape for PACE beyond the first 5 - year funded term.\nThe PACE programme is now looking for an external provider to develop and produce an interim impact review and report (that will build upon the existing baseline impact study completed in June 2025) to understand how key activities are progressing towards expected outcomes which can be compared to the findings from the baseline study and at the endline stage.\nThe overall purpose of the impact evaluation and this interim review is to be able to assess the impact of PACE on the AMR drug development ecosystem and on the development of drugs and diagnostics.",
    "tenderPeriod": {
      "endDate": "2026-01-09T14:00:00Z"
    },
    "enquiryPeriod": {
      "endDate": "2025-12-23T14:00:00Z"
    },
    "aboveThreshold": false,
    "submissionTerms": {
      "electronicSubmissionPolicy": "allowed"
    },
    "procurementMethod": "open",
    "mainProcurementCategory": "services",
    "submissionMethodDetails": "https://procontract.due-north.com/Advert/?advertId=37a0881b-dfd4-f011-813a-005056b64545",
    "procurementMethodDetails": "Below threshold - open competition"
  },
  "parties": [
    {
      "id": "GB-COH-09928547",
      "name": "MEDICINES DISCOVERY CATAPULT LIMITED",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKD62",
        "country": "GB",
        "locality": "Macclesfield",
        "postalCode": "SK10 4ZF",
        "countryName": "United Kingdom",
        "streetAddress": "Block 35g, Mereside Alderley Park"
      },
      "details": {
        "classifications": [
          {
            "id": "publicAuthoritySubCentralGovernment",
            "scheme": "UK_CA_TYPE",
            "description": "Public authority - sub-central government"
          }
        ]
      },
      "identifier": {
        "id": "09928547",
        "scheme": "GB-COH"
      },
      "contactPoint": {
        "email": "procurement@md.catapult.org.uk"
      },
      "additionalIdentifiers": [
        {
          "id": "PJPQ-6911-DQYY",
          "scheme": "GB-PPON"
        }
      ]
    }
  ],
  "language": "en",
  "initiationType": "tender"
}
Complete JSON history (2 releases)
9 Dec 2025 · 080894-2025 · tenderUpdate
{
  "id": "080894-2025",
  "tag": [
    "tenderUpdate"
  ],
  "date": "2025-12-09T09:26:03Z",
  "ocid": "ocds-h6vhtk-05f160",
  "buyer": {
    "id": "GB-COH-09928547",
    "name": "MEDICINES DISCOVERY CATAPULT LIMITED"
  },
  "tender": {
    "id": "ocds-h6vhtk-05f160",
    "lots": [
      {
        "id": "1",
        "value": {
          "amount": 50000,
          "currency": "GBP",
          "amountGross": 60000
        },
        "status": "active",
        "suitability": {
          "sme": true
        },
        "awardCriteria": {
          "criteria": [
            {
              "name": "Quality",
              "type": "quality",
              "numbers": [
                {
                  "number": 80,
                  "weight": "percentageExact"
                }
              ]
            },
            {
              "name": "Price",
              "type": "price",
              "numbers": [
                {
                  "number": 20,
                  "weight": "percentageExact"
                }
              ]
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2026-07-31T23:59:59+01:00",
          "startDate": "2026-02-02T00:00:00Z"
        }
      }
    ],
    "items": [
      {
        "id": "1",
        "relatedLot": "1",
        "deliveryAddresses": [
          {
            "region": "UK",
            "country": "GB",
            "countryName": "United Kingdom"
          }
        ],
        "additionalClassifications": [
          {
            "id": "79410000",
            "scheme": "CPV",
            "description": "Business and management consultancy services"
          }
        ]
      }
    ],
    "title": "PACE Interim Impact Report",
    "value": {
      "amount": 50000,
      "currency": "GBP",
      "amountGross": 60000
    },
    "status": "active",
    "documents": [
      {
        "id": "080894-2025",
        "url": "https://www.find-tender.service.gov.uk/Notice/080894-2025",
        "format": "text/html",
        "noticeType": "UK4",
        "description": "Tender notice on Find a Tender",
        "documentType": "tenderNotice",
        "datePublished": "2025-12-09T09:26:03Z"
      }
    ],
    "legalBasis": {
      "id": "2023/54",
      "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents",
      "scheme": "UKPGA"
    },
    "description": "PACE (Pathways to Antimicrobial Clinical Efficacy) is a £30 million initiative supporting and funding early-stage innovation in medicines and diagnostics, aimed at tackling AMR. It was established in September 2023 and is a collaboration between Innovate UK (IUK), LifeArc, and Medicines Discovery Catapult (MDC) - three leaders in the UK's health innovation and research community.\nPACE brings together the funding, resources, and partnerships to help innovators progress their early-stage antimicrobial drug and diagnostics projects with greater speed, support and confidence - giving the best AMR innovations the greatest chance of success. PACE will create a path to value through 3 strategic goals which will be underpinned by effective programme management and delivery:\nGrow a pipeline of high-quality antimicrobial drugs and associated diagnostics aligned with unmet needs and route to patient impact.\nProvide innovative researchers in Academia and SMEs located globally the funding, advice and support they need to build de-risked and investment ready assets\nConvene collaboration network(s) to identify barriers to innovation, advance programmes and drive new collaborative R&D.\nIt is a requirement of MDC's grant funding agreement with Innovate UK and LifeArc that the outcomes and long-term impacts of PACE activities are assessed at key time points throughout the programme's timeline.  The PACE programme is funded for an initial term of five years and as of April 2026 will reach its midway point in this funding cycle and so there is a need to conduct an interim review of progress towards expected outcomes.\nFindings from this interim review will directly inform programme refinement. Key to this will be the opportunity to gather feedback and learning from Round 1 beneficiaries and partners on the PACE Academy, the project management process, and the use of Enabling projects so far.  It will also allow the programme to capture the experiences of beneficiaries from Round 2 to date.  This will provide learning in how best to support the Round 2 beneficiaries and for the future Round 3 of funding which will be targeted at a second group of therapeutic companies.  It is expected that findings from the interim review will directly inform the need and shape for PACE beyond the first 5 - year funded term.\nThe PACE programme is now looking for an external provider to develop and produce an interim impact review and report (that will build upon the existing baseline impact study completed in June 2025) to understand how key activities are progressing towards expected outcomes which can be compared to the findings from the baseline study and at the endline stage.\nThe overall purpose of the impact evaluation and this interim review is to be able to assess the impact of PACE on the AMR drug development ecosystem and on the development of drugs and diagnostics.",
    "tenderPeriod": {
      "endDate": "2026-01-09T14:00:00Z"
    },
    "enquiryPeriod": {
      "endDate": "2025-12-23T14:00:00Z"
    },
    "aboveThreshold": false,
    "submissionTerms": {
      "electronicSubmissionPolicy": "allowed"
    },
    "procurementMethod": "open",
    "mainProcurementCategory": "services",
    "submissionMethodDetails": "https://procontract.due-north.com/Advert/?advertId=37a0881b-dfd4-f011-813a-005056b64545",
    "procurementMethodDetails": "Below threshold - open competition"
  },
  "parties": [
    {
      "id": "GB-COH-09928547",
      "name": "MEDICINES DISCOVERY CATAPULT LIMITED",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKD62",
        "country": "GB",
        "locality": "Macclesfield",
        "postalCode": "SK10 4ZF",
        "countryName": "United Kingdom",
        "streetAddress": "Block 35g, Mereside Alderley Park"
      },
      "details": {
        "classifications": [
          {
            "id": "publicAuthoritySubCentralGovernment",
            "scheme": "UK_CA_TYPE",
            "description": "Public authority - sub-central government"
          }
        ]
      },
      "identifier": {
        "id": "09928547",
        "scheme": "GB-COH"
      },
      "contactPoint": {
        "email": "procurement@md.catapult.org.uk"
      },
      "additionalIdentifiers": [
        {
          "id": "PJPQ-6911-DQYY",
          "scheme": "GB-PPON"
        }
      ]
    }
  ],
  "language": "en",
  "initiationType": "tender"
}
9 Dec 2025 · 080889-2025 · tender
{
  "id": "080889-2025",
  "tag": [
    "tender"
  ],
  "date": "2025-12-09T09:20:52Z",
  "ocid": "ocds-h6vhtk-05f160",
  "buyer": {
    "id": "GB-COH-09928547",
    "name": "MEDICINES DISCOVERY CATAPULT LIMITED"
  },
  "tender": {
    "id": "ocds-h6vhtk-05f160",
    "lots": [
      {
        "id": "1",
        "value": {
          "amount": 50000,
          "currency": "GBP",
          "amountGross": 60000
        },
        "status": "active",
        "suitability": {
          "sme": true
        },
        "awardCriteria": {
          "criteria": [
            {
              "name": "Quality",
              "type": "quality",
              "numbers": [
                {
                  "number": 80,
                  "weight": "percentageExact"
                }
              ]
            },
            {
              "name": "Price",
              "type": "price",
              "numbers": [
                {
                  "number": 20,
                  "weight": "percentageExact"
                }
              ]
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2026-07-31T23:59:59+01:00",
          "startDate": "2026-02-02T00:00:00Z"
        }
      }
    ],
    "items": [
      {
        "id": "1",
        "relatedLot": "1",
        "deliveryAddresses": [
          {
            "region": "UK",
            "country": "GB",
            "countryName": "United Kingdom"
          }
        ],
        "additionalClassifications": [
          {
            "id": "79410000",
            "scheme": "CPV",
            "description": "Business and management consultancy services"
          }
        ]
      }
    ],
    "title": "PACE Interim Impact Report",
    "value": {
      "amount": 50000,
      "currency": "GBP",
      "amountGross": 60000
    },
    "status": "active",
    "documents": [
      {
        "id": "080889-2025",
        "url": "https://www.find-tender.service.gov.uk/Notice/080889-2025",
        "format": "text/html",
        "noticeType": "UK4",
        "description": "Tender notice on Find a Tender",
        "documentType": "tenderNotice",
        "datePublished": "2025-12-09T09:20:52Z"
      }
    ],
    "legalBasis": {
      "id": "2023/54",
      "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents",
      "scheme": "UKPGA"
    },
    "description": "PACE (Pathways to Antimicrobial Clinical Efficacy) is a £30 million initiative supporting and funding early-stage innovation in medicines and diagnostics, aimed at tackling AMR. It was established in September 2023 and is a collaboration between Innovate UK (IUK), LifeArc, and Medicines Discovery Catapult (MDC) - three leaders in the UK's health innovation and research community.\nPACE brings together the funding, resources, and partnerships to help innovators progress their early-stage antimicrobial drug and diagnostics projects with greater speed, support and confidence - giving the best AMR innovations the greatest chance of success. PACE will create a path to value through 3 strategic goals which will be underpinned by effective programme management and delivery:\nGrow a pipeline of high-quality antimicrobial drugs and associated diagnostics aligned with unmet needs and route to patient impact.\nProvide innovative researchers in Academia and SMEs located globally the funding, advice and support they need to build de-risked and investment ready assets\nConvene collaboration network(s) to identify barriers to innovation, advance programmes and drive new collaborative R&D.  \nIt is a requirement of MDC's grant funding agreement with Innovate UK and LifeArc that the outcomes and long-term impacts of PACE activities are assessed at key time points throughout the programme's timeline.  The PACE programme is funded for an initial term of five years and as of April 2026 will reach its midway point in this funding cycle and so there is a need to conduct an interim review of progress towards expected outcomes.  \nFindings from this interim review will directly inform programme refinement. Key to this will be the opportunity to gather feedback and learning from Round 1 beneficiaries and partners on the PACE Academy, the project management process, and the use of Enabling projects so far.  It will also allow the programme to capture the experiences of beneficiaries from Round 2 to date.  This will provide learning in how best to support the Round 2 beneficiaries and for the future Round 3 of funding which will be targeted at a second group of therapeutic companies.  It is expected that findings from the interim review will directly inform the need and shape for PACE beyond the first 5 - year funded term.\nThe PACE programme is now looking for an external provider to develop and produce an interim impact review and report (that will build upon the existing baseline impact study completed in June 2025) to understand how key activities are progressing towards expected outcomes which can be compared to the findings from the baseline study and at the endline stage.  \nThe overall purpose of the impact evaluation and this interim review is to be able to assess the impact of PACE on the AMR drug development ecosystem and on the development of drugs and diagnostics.",
    "tenderPeriod": {
      "endDate": "2026-01-09T14:00:00Z"
    },
    "enquiryPeriod": {
      "endDate": "2025-12-23T14:00:00Z"
    },
    "aboveThreshold": false,
    "submissionTerms": {
      "electronicSubmissionPolicy": "allowed"
    },
    "procurementMethod": "open",
    "mainProcurementCategory": "services",
    "submissionMethodDetails": "https://supplierlive.proactisp2p.com/Account/Registration/Register",
    "procurementMethodDetails": "Below threshold - open competition"
  },
  "parties": [
    {
      "id": "GB-COH-09928547",
      "name": "MEDICINES DISCOVERY CATAPULT LIMITED",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKD62",
        "country": "GB",
        "locality": "Macclesfield",
        "postalCode": "SK10 4ZF",
        "countryName": "United Kingdom",
        "streetAddress": "Block 35g, Mereside Alderley Park"
      },
      "details": {
        "classifications": [
          {
            "id": "publicAuthoritySubCentralGovernment",
            "scheme": "UK_CA_TYPE",
            "description": "Public authority - sub-central government"
          }
        ]
      },
      "identifier": {
        "id": "09928547",
        "scheme": "GB-COH"
      },
      "contactPoint": {
        "email": "procurement@md.catapult.org.uk"
      },
      "additionalIdentifiers": [
        {
          "id": "PJPQ-6911-DQYY",
          "scheme": "GB-PPON"
        }
      ]
    }
  ],
  "language": "en",
  "initiationType": "tender"
}